AbCellera Stock Soars 64% on Promising Drug Candidate News

Shares of biotech firm AbCellera surged 64% in a single trading session after news emerged about the enormous potential market for one of its drug candidates currently in development. The company specializes in discovering and engineering antibodies for various diseases using artificial intelligence technology. The sharp rally reflects investors' high expectations for the drug's commercial success should it pass clinical trials and gain regulatory approval. Such spikes are typical in the biotech sector, where small and mid-cap stocks can swing wildly on drug development news. Analysts caution that the path from candidate to an approved drug remains long and risky, so investors should factor in the high volatility of such stocks.